.jpg "S100A4 IHC human Placenta (S100A4 1481)")
PDF DatasheetHuman and Mouse Anti-S100A4 Antibody Product Attributes
S100A4 Previously Observed Antibody Staining Patterns
Observed Subcellular, Organelle Specific Staining Data:
Anti-S100A4 antibody staining is expected to be primarily localized to the plasma membrane. There is variability in either the signal strength or the localization of signal in plasma membrane from cell to cell.
Observed Antibody Staining Data By Tissue Type:
Variations in S100A4 antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in hematopoietic cells in the bone marrow, macrophages in lung, non-germinal center cells in the lymph node, decidual cells in the placenta, cells in the red pulp in spleen and non-germinal center cells in the tonsil. More moderate antibody staining intensity was present in hematopoietic cells in the bone marrow, macrophages in lung, non-germinal center cells in the lymph node, decidual cells in the placenta, cells in the red pulp in spleen and non-germinal center cells in the tonsil. Low, but measureable presence of S100A4 could be seen inlymphoid tissue in appendix, peripheral nerve in mesenchymal tissue and squamous epithelial cells in the tonsil. We were unable to detect S100A4 in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of S100A4 expression as measured by anti-S100A4 antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| S100A4 Variability | + | + | + | ++ | ++ | + | + | + | ++ | ++ | ++ | ++ | ++ | + | + | + | ++ | + | ++ | ++ |
| S100A4 General Information | |
|---|---|
| Alternate Names | |
| S100 calcium-binding protein A4, S100A4, S100A4 | |
| Molecular Weight | |
| 10-12kDa | |
| Chromosomal Location | |
| 1q21 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | S100A4 |
| Entrez Gene ID | 6275 |
| Ensemble Gene ID | ENSG00000196154 |
| RefSeq Protein Accession(s) | NP_002952, NP_062427 |
| RefSeq mRNA Accession(s) | NM_002961, NM_019554 |
| RefSeq Genomic Accession(s) | NG_027993, NC_018912, NC_000001 |
| UniProt ID(s) | P26447 |
| UniGene ID(s) | P26447 |
| HGNC ID(s) | 10494 |
| Cosmic ID(s) | S100A4 |
| KEGG Gene ID(s) | hsa:6275 |
| PharmGKB ID(s) | PA34906 |
| General Description of S100A4. | |
| S100A4 belongs to the S100 super-family of proteins containing 2 EF-hand calcium-binding domains. S100 genes include at least 25 members, including S100A1-S100A18, trichohyalin, filaggrin, repetin, S100P, and S100Z. S100A4 exerts its function via direct interaction with a number of proteins including P53, P63, non-muscle myosin IIA, ?6?4 integrin, and liprin b1. S100A4 is overexpressed in highly metastatic cancers, which makes it useful as a marker of tumor progression. | |
-150x150.jpg)
There are no reviews yet.